Protagonist Therapeutics Announces Abstracts Selected for Oral and ...
Protagonist Therapeutics Announces Abstracts Selected for Oral and ...
Source: pr-inside.com
Page 2 - Session Date News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Session Date. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Session Date Today - Breaking & Trending Today
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting - uniQure (NASDAQ:QURE)
LEXINGTON, Mass. and AMSTERDAM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced
Source: benzinga.com
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
LEXINGTON, Mass. and AMSTERDAM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 12 data presentations, including two oral presentations, will be delivered at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting being held October 24-27 in Brussels, Belgium. “Our multiple presentations at ESGCT demonstrate uniQure’s continued leadership in a
Source: yahoo.com
Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas
/PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary,...
Source: prnewswire.com
Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023
/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...
Source: prnewswire.com